Latest acalabrutinib results and from ASH 2018: Dr. Mato on a new Triple Combination of Novel Drugs for CLL and Richter’s Transformation

[bkoffman]

Hi,

Things don’t slow down much in the CLL world. And that is a good thing. Just makes for a lot of writing for me to keep up.

In the last week we posted about the encouraging results in an acalabrutib trial and my interview with Dr. Mato at ASH 2018 about a new triplet therapy (Ublituximab (TG-1101), Umbralisib and Pembrolizumab) for CLL and the still formidable opponent, Richter’s Transformation. For more details and my explanation of the significance of this research, please visit the front page of our website: CLLSociety.org

Stay strong.

We are all in this together.

Brian

Brian Koffman MDCM DCFP, DABFM, MS Ed

Co-Founder, Executive VP and Chief Medical Officer

CLL Society, Inc.

[Justasheet1]

Doc,

That was great info. I usually just like your “take away points “. You cut to the chase.

Your link to the CllSociety in your post doesn’t work btw.

Get some rest, you deserve it.

Jeff

[johnl]

Do you know of any particular reason that they chose these drugs over Gazya and Idelilisib with a checkpoint inhibitor ?

john

[bkoffman CLL CURE Hero]

Try this link: cllsociety.org

[MsLockYourPosts Passed Volunteer in reply to bkoffman]

This one works for me.